Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus MYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus MYCHEL.
CHLOROMYCETIN vs MYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
Adults: 200 mg orally twice daily for 14 days.
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Category C
Category C
Antibiotic
Antibiotic